Demoson

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Demoson

Quick Facts

Property Description
Active Ingredient Mometasone Furoate
Pharmacological Class Corticosteroid (Glucocorticoid)
Origin Synthetic
Primary Forms Cream, Ointment, Solution, Nasal Spray
General Purpose Anti-inflammatory and Antipruritic

What is Demoson: Classification and Identity

Demoson is a medicinal preparation whose active compound is Mometasone Furoate, classified pharmacologically as a potent corticosteroid, specifically a glucocorticoid. This medication is a single-ingredient product, meaning its therapeutic effect relies exclusively on the Mometasone Furoate compound. The active substance is entirely synthetic, created in a laboratory to optimize its potent anti-inflammatory properties, a characteristic of many modern corticosteroids. Its identity as a powerful anti-inflammatory drug is rooted in its ability to modulate the body's immune response.


Mometasone Furoate Composition and Available Forms

The active substance, Mometasone Furoate, is combined with a specific base/vehicle to create the final product, which is intended for either topical (skin) or nasal application. Demoson is most commonly available as a cream, a heavier ointment, a lighter lotion or solution for cutaneous use, and an aqueous nasal spray for mucosal delivery. This variety of dosage forms ensures effective administration via different routes of administration. The formulation’s versatility in targeting both skin and mucosal membranes is a key differentiating factor, making it suitable for a broad spectrum of inflammatory issues affecting the surface tissues.


General Purpose and High-Level Action

The general purpose of Demoson is to provide powerful relief from inflammatory symptoms, specifically focusing on anti-inflammatory and antipruritic (anti-itching) effects. The drug achieves this by suppressing the cellular cascade that leads to inflammation, essentially calming the body’s overactive response. The compound's mechanism of action involves binding to glucocorticoid receptors and inhibiting various inflammatory processes. This high-level action, which includes the decreased synthesis of inflammatory mediators, is the fundamental mechanism through which the medication helps to manage and reduce symptoms like swelling, redness, and the often-debilitating sensation of itching associated with inflammation.

Regulatory References

  1. The anti-inflammatory and immunosuppressive effects of glucocorticoids

What side effects are possible with Demoson?

Possible Side Effects and Safety Information

The safety profile of Demoson, which contains Mometasone Furoate, is classified by regulatory authorities based on the frequency and system-organ class involved. Adverse reactions are primarily localized to the site of application.


Frequency-Classified Adverse Reactions

Adverse reactions associated with nasal application are listed with defined frequency categories in official labeling:

  • Very Common (occurs in 10% or more): Includes Headache, Epistaxis (nosebleed), Pharyngitis, and Viral Infection.
  • Common (occurs in 1% to 10%): Includes Nasal Burning or Irritation and Cough.

For topical use, Burning and Pruritus (Itching) are classified as Less Common/Uncommon reactions, which may also include signs of Skin Atrophy.


Systemic Risk and Serious Adverse Reactions

Although Mometasone Furoate is applied locally, there is a documented potential for systemic absorption leading to serious, less common adverse reactions, which are often reported with a Frequency Not Known status:

  • Endocrine Disorders: Potential for Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Hypercorticism.
  • Eye Disorders: Officially documented risks include the development of Glaucoma and Cataracts.
  • Respiratory Disorders: Nasal Septal Perforation has been reported with intranasal corticosteroid use.

Population-Specific and Exposure-Related Safety

Regulatory documentation notes that pediatric patients are specifically monitored for a potential reduction in growth velocity during long-term intranasal use. Furthermore, the risk of serious systemic effects is officially tied to exposure factors, increasing with prolonged use, application to large surface areas, or use under occlusive dressings.

High-level safety constraints include a contraindication for individuals with known hypersensitivity to the medicine or its ingredients.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below summarizes the overdose profile of Demoson, based on established regulatory documents.

Overdose with Demoson typically presents as a severe exaggeration of its expected effects on the nervous and respiratory systems. Documented clinical manifestations include severe somnolence, profound sedation, hypotension (low blood pressure), and bradycardia (slowed heart rate). Of particular concern is respiratory depression, which may progress to apnea (cessation of breathing), coma, and in severe cases, be fatal.

Risk of severe overdose increases substantially when Demoson is taken in doses far exceeding the maximum therapeutic dose or when combined with other central nervous system depressants, including alcohol.

Immediate Action Required

If an overdose is suspected or if severe symptoms occur (such as difficulty breathing, extreme drowsiness, or loss of consciousness), you must seek emergency medical assistance immediately.

Management in Healthcare Settings

Healthcare professionals managing a Demoson overdose will focus on establishing a clear airway and providing supportive care to maintain adequate respiration and blood pressure. Continuous monitoring of vital signs is essential. In certain clinical situations, specific pharmacological agents may be considered to counteract the effects of the overdose, as part of the overall supportive treatment strategy.

Therapeutic Uses of Demoson

The medication's therapeutic domain covers both inflammatory skin and nasal conditions. The medicine is applied to address a range of symptoms related to heightened physiological activity. Demoson is commonly used across conditions presenting with localized discomfort, specifically addressing Atopic Dermatitis (Eczema), Psoriasis, allergic rhinitis, and Nasal Polyps.

Management of Inflammatory and Allergic Symptoms

The medication is applied to ease the burden of chronic conditions characterized by episodic or fluctuating manifestations. The topical use may assist with addressing symptom clusters that focus on itching (pruritus), redness, and swelling that become more disruptive during flare-ups. This may provide support that helps ease the overall symptom burden and assists with maintaining functional stability during periods of distress.

“The treatment is commonly used when symptoms become difficult to tolerate and supportive management is appropriate.”

The nasal use is relevant in clinical settings marked by increased discomfort or tension, helping manage manifestations that create noticeable interference with daily stability, such as nasal congestion, runny nose, and sneezing. This may offer symptomatic relief that contributes to improved day-to-day comfort and helps patients cope more steadily with difficult allergic episodes.

Quick Fact: Relief for Symptom Domain
Itching Pruritic Skin Complaints
Congestion Allergic Nasal Obstruction

Eligibility and Restrictions for Use

Who Can and Cannot Use Demoson — Official Regulatory Information

The eligibility for using Demoson (Mometasone Furoate) is strictly defined by regulatory bodies through specific population criteria, contraindications, and restrictions on use.

Category Official Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) for most indications. Pediatric patients at specific minimum ages, such as ge 2 years for some topical creams or nasal forms, depending on the regulatory label.
Populations for whom use is contraindicated Patients with known hypersensitivity to Mometasone Furoate. Patients with an untreated localized infection (e.g., fungal, bacterial, viral) at the site of administration. Topical forms are contraindicated for conditions like facial rosacea, acne vulgaris, and perioral dermatitis.
Age-related eligibility rules Use in children under 2 years of age is not recommended for most topical forms as safety and efficacy are not established. Nasal forms for nasal polyps are restricted to adults 18 years and older.
Pregnancy and lactation eligibility Pregnancy: Use is conditional; it should be used only if the potential benefit justifies the potential risk to the fetus. Lactation: Use requires caution, as it is unknown if the drug passes into human milk.

Connection to the overall eligibility profile: The regulatory documents establish population boundaries through absolute contraindications (allergy, active infection), set strict minimum age thresholds that vary by indication, and impose conditional limitations based on physiological status (pregnancy/lactation) and pre-existing conditions at the treatment site.

What should I know about interactions with other medicines?

Demoson Interactions with other medicines and products

This section summarizes only the officially documented interaction information for the active ingredient, Mometasone Furoate, as found in government regulatory documents.

Documented Pharmacokinetic Interactions

The primary documented pharmacokinetic interaction involves the liver's enzyme system.

  • Interacting Products: Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors (e.g., Ritonavir, Ketoconazole, Cobicistat).
  • Mechanism as Stated in Label: These substances can inhibit the metabolism of Mometasone Furoate, leading to an increased systemic exposure to the corticosteroid.
  • Regulatory Status: Use with caution is advised for these combinations due to the risk of increased systemic corticosteroid effects, requiring patient monitoring.

Pharmacodynamic and Substance Interactions

Specific pharmacodynamic interactions have been noted for combination nasal spray products containing Mometasone Furoate and an antihistamine.

  • Interacting Substances: Alcohol or other Central Nervous System (CNS) Depressants.
  • Restriction: Concurrent use of the combination product with these substances should be avoided.
  • Official Effect: This restriction is due to the potential for additional reductions in alertness and additional impairment of CNS performance resulting from an additive effect.

Population-Specific Notes

The regulatory documents note that conditions such as hepatic impairment are factors that may affect the disposition and systemic exposure of Mometasone Furoate, potentially increasing the risk of systemic effects from interactions.

Mechanism of Action

The active ingredient, Mometasone Furoate, acts as an agonist for the intracellular Glucocorticoid Receptor ( GR). The activated complex enters the cell nucleus to perform transrepression, functionally interfering with pro-inflammatory transcription factors like NF-kappa B. This core action suppresses the genetic instructions for synthesizing inflammatory proteins, initiating the modulation of physiological pathways. Simultaneously, the nuclear complex triggers transactivation to induce anti-inflammatory proteins, such as Lipocortin-1. Lipocortin-1 inhibits the enzyme Phospholipase A2 ( PLA2), thereby restricting the conversion of membrane lipids into arachidonic acid. This blockade prevents the downstream formation of inflammatory mediators like prostaglandins and leukotrienes, leading to the physiological consequences of reduced fluid extravasation and diminished nerve signaling. The mechanism also induces localized vasoconstriction and modulates the function of immune cells. By constricting micro-vessels, the drug reduces the leakage of fluid and the influx of inflammatory cells into the affected tissue, resulting in a reduction of erythema due to local vasoconstriction.

Dosage and Administration Information

How to Use Demoson: Official Administration Guidelines

Demoson (Mometasone Furoate) is administered through distinct routes depending on the condition, following specific protocols established for the medication.

Administration Scope

Instruction Detail
Route of Administration Topical (for skin application) and Intranasal (via metered spray).
Dosing Schedule (Adult) Topical: Apply a thin film of the 0.1% cream/ointment once daily. Nasal: Typically two sprays (100 mu g) in each nostril once daily (Total Daily Dose: 200 mu g). The maximum daily nasal dose is 400 mu g.
Frequency Pattern Predominantly Once daily, with Twice daily as the maximum frequency for certain nasal indications.
Age-Group Rules The topical 0.1% cream is approved for patients 2 years of age and older. Nasal use is approved for children ge 3 years for allergic rhinitis at 100 mu g once daily.

Preparation and Procedural Constraints

The intranasal spray requires preparation before use. The device must be shaken well and primed with a set number of actuations prior to its initial administration. If the nasal spray remains unused for a specified period, such as 14 days or longer, it must be re-primed before the next dose.

For topical use, the formulation must not be applied with occlusive dressings (e.g., bandages) unless specifically directed. Furthermore, topical application should be discontinued once control is achieved, and the nasal dose should be titrated down to the lowest amount that maintains effectiveness.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Demoson

Evidence for Use in Atopic Dermatitis and Psoriasis (Skin Conditions)

Research exploring Demoson's use for inflammatory skin conditions involves short-term Randomized Controlled Trials (RCTs), comparative studies, and systematic reviews. The populations examined included adults and pediatric patients (children as young as 2 years old) with symptoms where symptoms may vary in intensity. Studies monitored outcomes related to physical discomfort, such as changes in specific clinical severity scores used to measure redness, scaling, and focusing on symptoms such as itching (pruritus). The evidence contributes to the broader landscape for short-term evaluations, and findings indicate patterns of measured change in clinical signs over the observed study periods.

However, certain research limitations exist. Follow-up durations were limited in many registration trials, meaning there is limited information for long-term outcomes regarding the effects of cumulative use or maintenance protocols beyond the first year of treatment. Comparative evidence is lacking concerning direct, head-to-head effects against all other steroid and non-steroid topical treatments across various formulations.


Evidence for Use in Allergic Rhinitis (Nasal Symptoms)

The research base for Demoson nasal spray is extensive, consisting of numerous Randomized Controlled Trials (RCTs) and meta-analyses. Studies explored measurements of symptoms such as congestion, sneezing, runny nose (rhinorrhea), and itching over time, using scoring systems like the Total Nasal Symptom Score (TNSS). Populations included adults, adolescents, and children (as young as 2 years old). The research so far indicates that the studies monitored the evolution of measurements in composite symptom scores over treatment periods that typically ranged from 2 weeks up to 12 weeks for use during an allergy season.

Comparative studies also explored whether the nasal spray had different measured patterns of response when compared to saline, with findings that were mixed in some specific subgroups. Long-term effects are not fully established regarding continuous, multi-year use, and comparative evidence is lacking to definitively show differing measured patterns of response over all other products within the same class; instead, many studies monitored patterns of similar measured effects.


Evidence for Use in Nasal Polyps

Demoson was evaluated in trials and pooled analyses that focused on adults diagnosed with bilateral nasal polyps. Research examined two main axes: the objective assessment of polyp size (measured by a graded scoring system) and the patient-reported outcome describing perceived discomfort from nasal obstruction/congestion. Findings describe patterns observed in the studies related to measurements of polyp physical size and changes in the reported sensation of blockage.

Frequently Asked Questions (FAQ)

Common questions about Demoson (FAQ)

Q: How quickly does Demoson start working?

The onset of the full therapeutic effect can vary depending on the specific product form and the condition being addressed. For topical use, official guidelines suggest that if no improvement is observed within two weeks, reassessment may be needed. This information provides a reference point regarding the observed timeframe for initial effects.


Q: Does Demoson interact with common pain relievers like ibuprofen?

Official regulatory documentation focusing on drug-drug interactions for Demoson (Mometasone Furoate) does not typically list non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen as known interacting medicines. Interactions are primarily documented with strong inhibitors of a specific liver enzyme.


Q: Can Demoson be taken with herbal supplements?

Official health guidance states that there is often insufficient information available regarding the safety of using Demoson with complementary or herbal supplements. These non-prescription products are not typically covered in the testing of prescription medicines.


Q: What does the research say about the long-term use of Demoson?

Regulatory documents note that for some forms and patient populations, such as pediatric topical use, safety and efficacy have not been established for treatment periods extending beyond a few weeks. The potential for systemic side effects, such such as effects on the body’s hormone balance, is noted in regulatory documents as a factor that may be influenced by prolonged use.


Q: Is it true that Demoson is only for temporary use?

Official administration guidance addresses the duration of use by stating that topical therapy should be discontinued once the skin condition is under control. For the nasal spray, the dose may be reduced to the lowest effective dose for maintenance, consistent with official guidelines.


Q: Does Demoson affect blood pressure?

Adverse reaction lists in the official regulatory documentation for localized Demoson do not commonly include changes in blood pressure or hypertension. The medication is primarily intended for local effects, and major systemic cardiovascular issues are not commonly listed as adverse reactions.


Q: Can I take Demoson if I have diabetes?

Demoson is a corticosteroid. Regulatory information indicates that use is typically approached with caution in individuals with diabetes mellitus or glucose intolerance, as systemic absorption may potentially affect blood glucose levels.


Q: Is Demoson the same kind of drug as [similar common drug name]?

Demoson's active ingredient, Mometasone Furoate, is classified pharmacologically as a potent corticosteroid, specifically a glucocorticoid. This means it is a synthetic anti-inflammatory medicine.


Q: How long can a person stay on Demoson?

The potential for systemic side effects, such as the suppression of the HPA axis (a hormonal feedback system), increases with prolonged use. Safety and efficacy are not established for continuous, multi-year use in many indications. Dosage adjustment guidelines are established in regulatory documents for patients who may require long-term control.


Q: Does Demoson affect fertility?

Official regulatory information, where available, indicates that there is no evidence that Demoson (Mometasone Furoate) affects fertility in either men or women.


Q: Is Demoson known to cause dry mouth?

For the nasal spray formulation, common adverse reactions listed in official documents include dryness or irritation of the nose and throat. This reported local effect is specific to the nasal application site.


Q: Are generic versions of Demoson available?

Official regulatory records, such as those maintained by the FDA, confirm that generic versions of Mometasone Furoate, the active ingredient in Demoson, are approved and available.


Q: What is the shelf life of Demoson?

Specific storage guidelines defined in official product documents include both the total shelf life for the sealed product and a defined discard period after the product has been opened or first used. For example, the nasal spray typically must be discarded two months after it is first used.


Q: What is the maximum daily nasal dose?

The maximum recommended total daily dose for the nasal spray formulation in adults, which is typically used for conditions like nasal polyps, is described in regulatory documents as 400 micrograms.


Q: What is the minimum age for all Demoson products?

Official regulatory documents define the minimum age based on indication and formulation. For certain topical products or nasal use for allergic rhinitis, the minimum age is 2 years. However, use for some conditions, such as nasal polyps, is restricted to adults 18 years and older.

How should Demoson be stored and disposed of?

How to Store and Dispose of Demoson

Official regulatory documents define strict conditions for the storage and disposal of Demoson (Mometasone Furoate) to ensure its quality and safety.


Storage Requirements

Detail Regulatory Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Prohibited Environment Do not freeze the product.
Container Keep in the original container and ensure it is tightly closed.
Child Safety Must be kept out of the reach and sight of children.

Stability and Disposal

The nasal spray formulation must be discarded 2 months after the first use. For disposal, the product and its container must not be thrown into wastewater or household waste. Unused or expired medication must be disposed of according to local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Demoson found in:

A-Z Index: